Results 21 to 30 of about 4,569 (133)

Rare concurrent ocular myasthenia gravis and Graves’ ophthalmopathy in a man with Poland syndrome: a case report

BMC Neurology, 2020
Background Ocular myasthenia gravis and Graves’ ophthalmopathy are autoimmune diseases that are mediated by membrane receptors and share many identical clinical processes.
Jingqun Tang, Chao Qin
doaj   +1 more source

Modified Deep Lateral Wall Decompression Surgery in the Treatment of Thyroid‐Associated Ophthalmopathy: A Retrospective Evaluation

Eye &ENT Research, Volume 3, Issue 1, Page 5-10, March 2026.
ABSTRACT Background Thyroid‐associated ophthalmopathy (TAO) may lead to severe exophthalmos and dysthyroid optic neuropathy (DON), which can threaten visual function. Orbital decompression surgery is often required when medical therapy is insufficient; however, traditional deep lateral wall decompression techniques remain associated with several ...
Shuo Wu, Jiahong Lao, Rongrong Ge, Zhaohui Shi, Qintai Yang   +4 more
wiley   +1 more source

Clinical and Radiological Findings in Patients with Newly Diagnosed Graves’ Ophthalmopathy

International Journal of Endocrinology, 2021
Background. Graves’ ophthalmopathy is the most common extrathyroidal manifestation of Graves’ disease. The objective of this study was to investigate the clinical ophthalmological and MRI findings in newly diagnosed Graves’ ophthalmopathy. Methods.
Yakup Cevik, Hande Taylan Sekeroglu, Burce Ozgen, Kadriye Erkan Turan, Ali Sefik Sanac   +4 more
doaj   +1 more source

Retinal Capillary Density Reduction Contributes to Dysthyroid Optic Neuropathy via an L‐Arginine‐NO Pathway: A Metabonomics and Clinical Trial Study

MedComm, Volume 7, Issue 3, March 2026.
Oxidative stress induces endothelial nitric oxide synthase (eNOS) uncoupling and L‐arginine depletion, reducing nitric oxide (NO) bioavailability in vascular endothelium and contributing to decreased retinal capillary density (RCD) in dysthyroid optic neuropathy (DON).
Yunhai Tu, Congcong Yan, Lu Chen, Weijie Liu, Xiaozhou Hu, Mengyuan Gao, Wei Rao, Jiayi Zhang, Junye Zhu, Hui Wu, Kang Zhang, Meng Zhou, Wencan Wu   +12 more
wiley   +1 more source

“Influence of Clinically Active Graves’ Ophthalmopathy on Spherical Equivalent and Visual Acuity”

Clinical Ophthalmology, 2022
Jasenka Petrovic Jurcevic,1 Marko Jurcevic,2 Mateja Jagic,3 Anamarija Jazbec,4 Kresimir Mandic,5 Jelena Juri Mandic5 1Medical School University of Zagreb, PhD Candidate on the Programme “Biomedicine and Health”, Zagreb, Croatia; 2University of Zagreb ...
Petrovic Jurcevic J, Jurcevic M, Jagic M, Jazbec A, Mandic K, Juri Mandic J   +5 more
doaj  

Research progress on the pathogenesis of Graves’ ophthalmopathy: Based on immunity, noncoding RNA and exosomes

Frontiers in Immunology, 2022
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng, Jingyi Zheng, Honghong Duan, Sufang You, Sufang You, Bo Liang, Yuping Chen, Yuping Chen, Huibin Huang   +8 more
doaj   +1 more source

The Diagnostic Value of Mean Apparent Propagator‐MRI in Dysthyroid Optic Neuropathy: A Quantitative Analysis of the Entire Visual Pathway

CNS Neuroscience &Therapeutics, Volume 32, Issue 2, February 2026.
The diagnostic model combining orbital and intracranial MAP‐MRI parameters could significantly optimize diagnostic efficiency of dysthyroid optic neuropathy. Comprehensive MAP‐MRI parameters analysis of the entire visual pathway enables a deeper understanding of disease involvement, provides novel insights into the early accurate diagnosis and ...
Mengsha Zou, Dide Wu, Yanglei Cheng, Haodong Qin, Zhiyun Yang, Shubin Hong, Hongzhang Zhu, Cui Yan   +7 more
wiley   +1 more source

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody

Case Reports in Endocrinology, 2018
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta, Tomohiro Tanaka, Haruka Kato, Shota Kakoi, Yuki Shimizu, Chie Hasegawa, Akiko Hayakawa, Satoshi Yasuda, Kento Ogawa, Shunsuke Ito, Hideomi Ohguchi, Takashi Yagi, Hiroyuki Koyama, Mihoko Kawamura, Kazuhiko Sugitani, Yuichiro Ogura, Takashi Joh, Kenro Imaeda   +17 more
doaj   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source